Marijuana smoking vs cannabinoids for glaucoma therapy

Archives of Ophthalmology

Volumn 116, Issue 11, 1998, Pages 1433-1437

  Green, Keith ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; DEXANABINOL; DRONABINOL; LATANOPROST; TIMOLOL MALEATE;

ARTICLE; CARCINOGENICITY; DIPLOPIA; DRUG ACTIVITY; DRUG APPROVAL; DRUG INDICATION; DRUG SCREENING; EMPHYSEMA; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAOCULAR PRESSURE; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SMOKING; TOPICAL DRUG ADMINISTRATION;

EID: 0031743712     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.116.11.1433     Document Type: Article

References (82)

1. Green K. The ocular effects of cannabinoids. In: Zadunaisky JA, Davson H, eds. Current Topics in Eye Research. Orlando, Fla: Academic Press Inc; 1979;1:175-215.
2. Green K. Current status of basic and clinical marihuana research in ophthalmology. In: Leopold IH, Burns RP, eds. Symposium on Ocular Therapy, New York, NY: John Wiley & Sons Inc: 1979;11:37-49.
3. Green K. Marihuana and the eye: a review. J Toxicol Cutan Ocul Toxicol. 1982;1:3-32.
4. Green K. Marijuana effects on intraocular pressure. In: Drance SM, Neufeld AH, eds. Glaucoma: Applied Pharmacology in Medical Treatment New York, NY: Grune & Stratton Inc; 1984:507-526.
5. Mechoulam R, Lander M, Srebnik M, et al. Recent advances in the use of cannabinoids as therapeutic agents. In: Agurell S, Dcwey WL, Willette RE, eds. The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects, Orlando, Fla: Academic Press Inc; 1984:777-793.
6. Green K, McDonald TF. Ocular toxicology of marijuana: an update. J Toxicol Cutan Ocul Toxicol. 1987;6:309-334.
7. Green K. History of ophthalmic toxicology. In: Chiou GCY, ed. Ophthalmic Toxicology. New York, NY: Raven Press; 1992:1-16.
8. Waller CW, Nair RS, McAllister AF, Urbanak B, Turner CE. Marihuana: An Annotated Bibliography. Vol 2. New York, NY: MacMillan Publishing Co Inc; 1982.
9. Fehr KO, Kalant H, eds. Adverse Health:.and behavioral Consequences of Cannabis Use. Toronto, Ontario: Addictive Research Foundation; 1983.
10. Nahas GG, ed. Marihuana in Science and Medicine. New York, NY: Raven Press; 1984.
11. Workshop on the Medical Utility of Marijuana: Report to the Director. Washington, DC: National Institutes of Health; 1997.
12. Nahas GG, Sutin KN, Agurell S, eds. Marijuana and Medicine. Totawa, NJ: Humana Press. In press.
13. Agurell S, Dewey WL, Willette RE, eds. The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects. Orlando, Fla: Academic Press Inc; 1964.
14. Graham IDP. Cannabis and Health. Orlando, Fla: Academic Press Inc; 1976.
15. Dewey WL. Cannabinoid pharmacology Pharmacol. Rev. 1986;38:151-178.
16. Tashkin DP, Shapiro BJ, Ramanna L, Taplin GV, Lee YE, Harper CE. Chronic effects of heavy marihuana smoking on pulmonary-function in healthy young males. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York, NY: Raven Press; 1976:291-295.
17. Rosenkrantz H, Fleischman RW. Effects of cannabis on lungs. In: Nahas GG, Paton WDM, eds. Marihuana: Biological Effects: Elmsford, NY: Pergamon Press Inc; 1979:279-299.
18. Dornbush RL, Kokkevi A. The acute effects of various cannabis substances on cognitive, perceptual and motor performance in very long-term hashish users. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York, NY: Raven Press; 1976:421-427.
19. Marihuana and Health, Washington, DC: National Academy of Sciences, Institute of Medicine Report; 1982.
20. Murray JB. Marijuana's effects on human cognitive functions, psychomotor functions, and personality. J Gen Psychol. 1986;113:23-55.
21. Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1986;34:605-613.
22. Leon-Carrion J. Mental performance in long-term heavy cannabis: a preliminary report. Psychol Rep. 1990;67:947-952.
23. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993,365:61-65.
24. Howlett AC. Pharmacology of cannabinoid receptors. Ann Rev Pharmacol Toxicol. 1995;35:607-634.
25. Solowij N. Do cognitive impairments recover fallowing cessation of cannabis use? Life Sci. 1995;5:2119-2126.
26. Solowij N, Michie PT, Fox AM. Differential Impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry. 1995;37:731-739.
27. Fletcher JM, Page JB, Francis DJ, et al. Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry. 1996;53:1051-1057.
28. Pope HG. Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA. 1996;275:521-527.
29. Mechoulam R, Feigenbaum JJ, Lander N, et al. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia. 1988;44:762-764.
30. 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology. 1990;29:161-165.
31. D'Ambra TE, Estep KG, Bell MR, et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective. (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem. 1992;35:124-135.
32. 9-tetrahydrocannabinol. J Pharmacol Exp Ther. 1992;263:1118-1126.
33. Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther. 1994;268:1612-1613.
34. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1959.
35. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol. 1993;231:313-314.
36. Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, Haycock DA. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther. 1993;264:1351-1363.
37. Abadji V, Lin S, Taha G, et al. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem. 1994;37:1889-1893.
38. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid in mice. J Pharmacol Exp Ther. 1994:270:219-227.
39. Hepler RS, Frank IM, Petrus R. Ocular effects of marijuana smoking. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York, NY: Raven Press; 1976:815-824.
40. Perez-Reyes M, Wagner D, Wall ME, Davis KH. Intravenous administration of cannabinoids on intraocular pressure. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York, NY: Raven Press: 1976:829-832.
41. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980;87:222-228.
42. Jones RT, Benowitz N. The 30-day trip: clinical studies of cannabis tolerance and dependence. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York, NY: Raven Press; 1976:627-642.
43. Dawson WW, Jiminez-Antillon CF, Perez JM, Zeskind JA. Marihuana and vision after ten years' use in Costa Rica. Invest Ophthalmol. 1977;16:689-699.
44. Hepler RS, Frank IM, Ungerleider JT. Pupillary constriction after marijuana smoking. Am J Ophthalmol. 1972;74:1185-1190.
45. Brown B, Adams M, Halgerstrom-Portnoy G, Jones RT, Flom MC. Pupil size after use of marijuana and alcohol. Am J Ophthalmol. 1977;83:350-354.
46. Hepler RS, Petrus R. Experiences with administration of marihuana to glaucoma patients. In: Cohen S, Stillman RC, eds. The Therapeutic Potential of Marihuana. New York, NY: Plenum Publishing Corp; 1976:63-75.
47. Green K, Bowman KA. Effect of marihuana derivatives on intraocular pressure. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York, NY: Raven Press; 1976:603-813.
48. Green K, Symonds CM, Oliver NW, Elijah RD. Intraocular pressure following systemic administration of cannabinoids. Curr Eye Res. 1982-1983;2:247-253.
49. El-Sohty MA, Harland EC, Benigni DA, Waller CW. Cannabinoids in glaucoma, II: the effect of different cannabinoids on intraocular pressure of the rabbit. Curr Eye Res. 1984;3:841-850.
50. Waller CW, Benigni DA, Harland EC, Bedford JA, Murphy JC, El-Sohly MA. Cannabinoids in glaucoma, III: the effects of different cannabinoids on intraocular pressure in the monkey. In: Agurell S, Dewey WL, Willette RE, eds. The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects. Orlando, Fla: Academic Press Inc; 1984:871-880.
51. Green K, Wynn H, Bowman K. A comparison of topical cannabinoids on intraocular pressure. Exp Eye Res. 1978;27:239-246.
52. Howes JF. Antiglaucoma effects of topically and oralty administered cannabinoids. In: Agurell S, Dewey WL, Willette RE, eds. The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects. Orlando, Fla: Academic Press Inc; 1984:881-890.
53. 9-tetrahydrocannabinol as a potential glaucoma agent. Glaucoma. 1982;4:253-255.
54. 9-tetrahydrocannabinol on intraocular pressure in dogs. Glaucoma. 1981;3:13-16.
55. Green K, Bigger JF, Kim L, Bowman K. Cannabinoid penetration and chronic effects in the eye. Exp Eye Res. 1977;24:197-205.
56. 9-tetrahydrocannabinol. Ann Ophthalmol. 1981;13:1219-1222.
57. 9-tetrahydrocannabinol in humans. J Pharm Pharmacol. 1981;33:40-41.
58. 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin Pharmacol. 1931;21(suppl 8-9):467S-471S.
59. 9-tetrahydrocannabinol in man. Arch Ophthalmol. 1982;100:265-267.
60. 9-tetrahydrocannabinol in human eyes. Arch Ophthalmol. 1983;101:591-593.
61. Beilin M, Aviv H, Friedman D, et al. HU2 11, a novel synthetic, non-psychotropic cannabinoid with ocular hypotensive activity [abstract]. Invest Ophthalmol Vis Sci. 1993;34(suppl):1113.
62. Sugrue MF. New approaches to antiglaucoma therapy. J Med Chem. 1997;40:2793-2809.
63. 9-tetrahydrocannabinol for refractory vomiting Induced by cancer chemotherapy. JAMA. 1980;243:1241-1243.
64. 9-tetrahydrocannabinol in clinical oncology. JAMA. 1981;245:2047-2051.
65. Schwartz RH, Voth EA, Sheridan MJ. Marijuana to prevent nausea and vomiting in cancer patients: a survey of clinical oncologists. South Med J. 1997;90:167-172.
66. Allen T, Tetrahydrocannabinol and chemotherapy [letter]. N Engl J Med. 1976;294:168.
67. Turner CE, El-Sohly MA, Boeren EG. Constituents of Cannabis sativa (L), XVII: a review of the natural constituents. J Nat Prod. 1980;43:169-234.
68. Doorenbos NJ, Fetterman PS, Quimby MW, Turner CE. Cultivation, extraction and analysis of Cannabis sativa (L). Ann N Y Acad Sci. 1971;191:3-14.
69. Ross SA, El-Sohly MA. Constituents of Cannabis sativa L, XXVIII: a review of the natural constituents: 1980-1984. Zagazig J Pharm Sci. 1995;4:1-10.
70. Green K, Kim K. Acute dose response of intraocular pressure to topical and oral cannabinoids. Proc Soc Exp Biol Med. 1977;154:228-231.
71. Mechoulam R, Lander N, Varkony TH, et al. Stereochemical requirements for cannabinoid activity. J Med Sci. 1980;23:1068-1072.
72. Newell FW, Stark P, Jay WM, Schanzlin DJ. Nabilone: a pressure-reducing synthetic benzopyran in open-angle glaucoma. Ophthalmology. 1979;86:156-160.
73. Lemberger L. Potential therapeutic usefulness of marijuana. Ann Rev Pharmacol Toxicol. 1980;20:151-172.
74. Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol Rev. 1986;38:75-149.
75. Sugrue MF, Funk HA, Leonard Y, O'Neill-Davis L, Labelle M. The ocular hypotensive effects of synthetic cannabinoids [abstract]. Invest Ophthalmol Vis Sci. 1996;37(suppl):831.
76. Pate DW, Jarvinen K, Urtti A, Harho P, Jarvinen T. Arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Curr Eye Res. 1995;14:791-797.
77. Pate DW, Jarvinen K, Urtti A, et al. Effects of topical anandamides on intraocular pressure in normotensive rabbits. Life Sci. 1996;58:1849-1860.
78. Hodges LC, Reggio PH, Green K. Evidence against cannabinoid receptor involvement in intraocular pressure: effects of cannabinoids in rabbits. Ophthalmic Res. 1997;29:1-5.
79. Hollister LE, Gillespie HK. Delta-8- and delta-9-tetrahydrocannabinol: comparison in man by oral and intravenous administration. Clin Pharm Ther. 1973;14:353-357.
80. Wall ME, Brine DR, Perez-Reyes M. Metabolism of cannabinoids in man. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York, NY: Raven Press; 1976:93-113.
81. Green K. Marijuana and intraocular pressure: possible mechanisms of action. In: Nahas GG, Sutin KN, Agurell S, eds. Marijuana and Medicine. Totawa, NJ: Humana Press. In press.
82. Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med. 1997;126:791-798.